ASLAN Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
ASLAN Pharmaceuticals (Nasdaq: ASLN) announced participation by CEO Dr. Carl Firth in two virtual health conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ASLAN Pharmaceuticals (Nasdaq: ASLN) announced participation by CEO Dr. Carl Firth in two virtual health conferences. The first, the Piper Sandler 33rd Annual Virtual Healthcare Conference, will feature a recorded discussion available on November 22, 2021, at 10:00 am ET. The second event is the 4th Annual Evercore ISI HealthCONx Conference, scheduled for December 2, 2021, at 8:50 am ET, located in Track 3. Both discussions can be accessed later on ASLAN's Investor Relations website.
Details
News Market Reaction – ASLN
The recorded move for ASLN in the trading session of this news was -5.59%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif. and SINGAPORE, Nov. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will be participating in fireside chats at two upcoming virtual health conferences. The details are as follows:
Piper Sandler 33rd Annual Virtual Healthcare Conference
- Recorded discussion available: November 22, 2021, at 10:00 am ET
4th Annual Evercore ISI HealthCONx Conference
- Date and time: Thursday, December 2, 2021, at 8:50 am ET
- Location: Track 3
Both discussions will be accessible afterwards within the News & Events section of ASLAN’s Investor Relations website at https://ir.aslanpharma.com/.
Media and IR contacts
| Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: ASLAN@spurwingcomms.com | Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: arr@lifesciadvisors.com |
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.